Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older
• People whose overall health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scale called the ECOG scale (scores 0 to 2)
• People with a life expectancy of at least 12 weeks
• People with a confirmed diagnosis of CD20-positive marginal zone lymphoma (MZL) — including splenic, nodal, or extranodal subtypes — based on an internationally recognised classification system
• People who have at least one measurable area of disease visible on a CT or MRI scan
• People whose MZL meets the treatment criteria set out in NCCN guidelines and who have not previously received any systemic treatment for MZL
• People whose major organs (such as liver, kidneys, and heart) are functioning normally
• Women who could become pregnant must have had a negative pregnancy test within 7 days before joining, and must be willing to use effective contraception during the trial and for 8 weeks after the last dose; men must agree to use effective contraception during the trial and for 8 weeks after the last dose, or must have had a surgical sterilisation procedure
• People who are willing to voluntarily participate, sign a consent form, follow the study requirements, and attend follow-up appointments

Who may not be able to join:

• People whose lymphoma has spread to the central nervous system (brain or spinal cord)
• People with a history of, or currently having, another untreated cancer — except for certain cancers considered fully cured, such as some types of skin cancer (basal cell carcinoma), early-stage cervical cancer (cervical carcinoma in situ), or superficial bladder cancer
• People with significant heart conditions, including moderate-to-severe reduced blood flow to the heart or a past heart attack, certain irregular heart rhythms (including specific abnormal readings on a heart tracing test), or moderate-to-severe heart failure, or a weakened pumping function of the heart (below 50% on an ultrasound test)
• People with blood clotting problems or who are currently receiving blood-thinning (anticoagulant) or clot-dissolving therapy
• People who have had a stroke, mini-stroke (TIA), brain bleed, deep vein blood clot, or pulmonary embolism (blood clot in the lungs) within the 12 months before joining
• People with a known inherited or acquired tendency to bleed or form clots (such as haemophilia, clotting disorders, low platelet counts, or an enlarged spleen affecting blood cell levels)
• People who have had a major operation, serious injury, fracture, or non-healing wound within the 4 weeks before joining
• People who have difficulty absorbing oral (swallowed) medications — for example, due to an inability to swallow, ongoing severe diarrhoea, or a bowel blockage
• People with an active infection currently requiring antibiotic, antiviral (other than treatment for chronic hepatitis B), or antifungal medication
• People with active hepatitis B or active hepatitis C infections, based on specific blood test results
• People with a history of substance misuse that they are unable to stop, or people with a mental health disorder that could affect participation
• People who have taken part in another clinical trial of an anticancer drug within the 4 weeks before joining
• People who have taken strong CYP3A4 inhibitor medications within 7 days before joining, or strong CYP3A4 inducer medications within 12 days before joining (these are specific types of drugs that can affect how other medications are processed in the body — confirm with the trial site which medications this applies to)
• Women who are pregnant or breastfeeding, or people of childbearing potential who are unwilling or unable to use effective contraception
• People whom the trial investigators consider unsuitable for any other reason that might affect the safety of the study or the reliability of its results

Important: Always verify eligibility with the trial site directly before applying.